1
|
Cucuzza S, Brosig S, Serno T, Bechtold-Peters K, Cerar J, Kammüller M, Gallou F. Modular and tunable alternative surfactants for biopharmaceuticals provide insights into Surfactant's Structure-Function relationship. Int J Pharm 2024; 650:123692. [PMID: 38081561 DOI: 10.1016/j.ijpharm.2023.123692] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2023] [Revised: 12/06/2023] [Accepted: 12/07/2023] [Indexed: 12/19/2023]
Abstract
Surface-induced aggregation of protein therapeutics is opposed by employing surfactants, which are ubiquitously used in drug product development, with polysorbates being the gold standard. Since poloxamer 188 is currently the only generally accepted polysorbate alternative, but cannot be ubiquitously applied, there is a strong need to develop surfactant alternatives for protein biologics that would complement and possibly overcome known drawbacks of existing surfactants. Yet, a severe lack of structure-function relationship knowledge complicates the development of new surfactants. Herein, we perform a systematic analysis of the structure-function relationship of three classes of novel alternative surfactants. Firstly, the mode of action is thoroughly characterized through tensiometry, calorimetry and MD simulations. Secondly, the safety profiles are evaluated through cell-based in vitro assays. Ultimately, we could conclude that the alternative surfactants investigated possess a mode of action and safety profile comparable to polysorbates. Moreover, the biophysical patterns elucidated here can be exploited to precisely tune the features of future surfactant designs.
Collapse
Affiliation(s)
- Stefano Cucuzza
- Novartis Pharma AG, TRD Biologics & CGT, GDD, 4002 Basel, Switzerland
| | - Sebastian Brosig
- Novartis Pharma AG, TRD Biologics & CGT, GDD, 4002 Basel, Switzerland
| | - Tim Serno
- Novartis Pharma AG, TRD Biologics & CGT, GDD, 4002 Basel, Switzerland
| | | | - Jure Cerar
- Novartis Pharma AG, TRD Biologics & CGT, GDD, 1234 Menges, Slovenia
| | | | | |
Collapse
|
2
|
Brosig S, Cucuzza S, Serno T, Bechtold-Peters K, Buecheler J, Zivec M, Germershaus O, Gallou F. Not the Usual Suspects: Alternative Surfactants for Biopharmaceuticals. ACS Appl Mater Interfaces 2023. [PMID: 37450418 DOI: 10.1021/acsami.3c05610] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/18/2023]
Abstract
Therapeutically relevant proteins naturally adsorb to interfaces, causing aggregation which in turn potentially leads to numerous adverse consequences such as loss of activity or unwanted immunogenic reactions. Surfactants are ubiquitously used in biotherapeutics drug development to oppose interfacial stress, yet, the choice of the surfactant is extremely limited: to date, only polysorbates (PS20/80) and poloxamer 188 are used in commercial products. However, both surfactant families suffer from severe degradation and impurities of the raw material, which frequently increases the risk of particle generation, chemical protein degradation, and potential adverse immune reactions. Herein, we assessed a total of 40 suitable alternative surfactant candidates and subsequently performed a selection through a three-gate screening process employing four protein modalities encompassing six different formulations. The screening is based on short-term agitation-induced aggregation studies coupled to particle analysis and surface tension characterization, followed by long-term quiescence stability studies connected to protein purity measurements and particle analysis. The study concludes by assessing the surfactant's chemical and enzymatic degradation propensity. The candidates emerging from the screening are de novo α-tocopherol-derivatives named VEDG-2.2 and VEDS, produced ad hoc for this study. They display protein stabilization potential comparable or better than polysorbates together with an increased resistance to chemical and enzymatic degradation, thus representing valuable alternative surfactants for biotherapeutics.
Collapse
Affiliation(s)
- Sebastian Brosig
- Novartis Pharma AG, GDD, TRD Biologics & CGT, Basel CH-4002, Switzerland
| | - Stefano Cucuzza
- Novartis Pharma AG, GDD, TRD Biologics & CGT, Basel CH-4002, Switzerland
| | - Tim Serno
- Novartis Pharma AG, GDD, TRD Biologics & CGT, Basel CH-4002, Switzerland
| | | | - Jakob Buecheler
- Novartis Pharma AG, GDD, TRD Biologics & CGT, Basel CH-4002, Switzerland
| | - Matej Zivec
- Novartis Pharma AG, GDD, TRD Biologics & CGT, Menges 1234, Slovenia
| | - Oliver Germershaus
- School of Life Sciences, University of Applied Sciences Northwestern Switzerland, Hofackerstrasse 30, Muttenz 4132, Switzerland
| | - Fabrice Gallou
- Novartis Pharma AG, GDD, CHAD, Basel CH-4057, Switzerland
| |
Collapse
|
3
|
Morales AM, Sreedhara A, Buecheler J, Brosig S, Chou D, Christian T, Das T, de Jong I, Fast J, Jagannathan B, Moussa EM, Nejadnik MR, Prajapati I, Radwick A, Rahman Y, Singh S. Correction: End-to-End Approach to Surfactant Selection, Risk Mitigation, and Control Strategies for Protein-Based Therapeutics. AAPS J 2023; 25:15. [PMID: 36631711 DOI: 10.1208/s12248-023-00780-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Affiliation(s)
- Annette Medina Morales
- Dosage Form Design and Development, BioPharmaceuticals Development, R&D, AstraZeneca, 1 Medimmune Way, Gaithersburg, MD, 20878, USA.
| | | | - Jakob Buecheler
- Technical Research Development, Novartis Pharma AG, 4002, Basel, Switzerland
| | - Sebastian Brosig
- Technical Research Development, Novartis Pharma AG, 4002, Basel, Switzerland
| | - Danny Chou
- Compassion BioSolution, LLC, Lomita, CA, 90717, USA
| | | | - Tapan Das
- Analytical Development and Attribute Sciences, Bristol Myers Squibb, New Brunswick, NJ, USA
| | - Isabella de Jong
- Genentech, Pharmaceutical Development, South San Francisco, CA, 94080, USA
| | - Jonas Fast
- Pharmaceutical Development, F. Hofmann-La Roche Ltd, CH-4070, Basel, Switzerland
| | | | - Ehab M Moussa
- Drug Product Development, AbbVie, North Chicago, IL, 60064, USA
| | - M Reza Nejadnik
- Department of Pharmaceutical Sciences & Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, 52242, USA
| | - Indira Prajapati
- Dosage Form Design and Development, BioPharmaceuticals Development, R&D, AstraZeneca, 1 Medimmune Way, Gaithersburg, MD, 20878, USA
| | | | - Yusra Rahman
- Department of Pharmaceutical Sciences & Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, 52242, USA
| | - Shubhadra Singh
- GlaxoSmithKline R&D, Biopharmaceutical Product Sciences, Collegeville, Philadelphia, PA, 19426, USA
| |
Collapse
|
4
|
Morales AM, Sreedhara A, Buecheler J, Brosig S, Chou D, Christian T, Das T, de Jong I, Fast J, Jagannathan B, Moussa EM, Nejadnik MR, Prajapati I, Radwick A, Rahman Y, Singh S. End-to-End Approach to Surfactant Selection, Risk Mitigation, and Control Strategies for Protein-Based Therapeutics. AAPS J 2022; 25:6. [PMID: 36471030 DOI: 10.1208/s12248-022-00773-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2022] [Accepted: 10/31/2022] [Indexed: 12/12/2022] Open
Abstract
A survey performed by the AAPS Drug Product Handling community revealed a general, mostly consensus, approach to the strategy for the selection of surfactant type and level for biopharmaceutical products. Discussing and building on the survey results, this article describes the common approach for surfactant selection and control strategy for protein-based therapeutics and focuses on key studies, common issues, mitigations, and rationale. Where relevant, each section is prefaced by survey responses from the 22 anonymized respondents. The article format consists of an overview of surfactant stabilization, followed by a strategy for the selection of surfactant level, and then discussions regarding risk identification, mitigation, and control strategy. Since surfactants that are commonly used in biologic formulations are known to undergo various forms of degradation, an effective control strategy for the chosen surfactant focuses on understanding and controlling the design space of the surfactant material attributes to ensure that the desired material quality is used consistently in DS/DP manufacturing. The material attributes of a surfactant added in the final DP formulation can influence DP performance (e.g., protein stability). Mitigation strategies are described that encompass risks from host cell proteins (HCP), DS/DP manufacturing processes, long-term storage, as well as during in-use conditions.
Collapse
Affiliation(s)
- Annette Medina Morales
- Dosage Form Design and Development, BioPharmaceuticals Development, R&D, AstraZeneca, 1 Medimmune Way, Gaithersburg, Maryland, 20878, USA.
| | - Alavattam Sreedhara
- Genentech, Pharmaceutical Development, South San Francisco, California, 94080, USA
| | - Jakob Buecheler
- Technical Research and Development, Novartis Pharma AG, 4002, Basel, Switzerland
| | - Sebastian Brosig
- Technical Research and Development, Novartis Pharma AG, 4002, Basel, Switzerland
| | - Danny Chou
- Compassion BioSolution, LLC, Lomita, California, 90717, USA
| | | | - Tapan Das
- Analytical Development and Attribute Sciences, Bristol Myers Squibb, New Brunswick, New Jersey, USA
| | - Isabella de Jong
- Genentech, Pharmaceutical Development, South San Francisco, California, 94080, USA
| | - Jonas Fast
- Pharmaceutical Development, F. Hoffmann-La Roche Ltd, CH-4070, Basel, Switzerland
| | | | - Ehab M Moussa
- Drug Product Development, AbbVie, North Chicago, Illinios, 60064, USA
| | - M Reza Nejadnik
- Department of Pharmaceutical Sciences & Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, Iowa, 52242, USA
| | - Indira Prajapati
- Dosage Form Design and Development, BioPharmaceuticals Development, R&D, AstraZeneca, 1 Medimmune Way, Gaithersburg, Maryland, 20878, USA
| | | | - Yusra Rahman
- Department of Pharmaceutical Sciences & Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, Iowa, 52242, USA
| | - Shubhadra Singh
- GlaxoSmithKline R&D, Biopharmaceutical Product Sciences, Collegeville, Philadelphia, Pennsylvania, 19426, USA
| |
Collapse
|
5
|
Kalden P, Schoeffl I, Rottermann K, Löffelbein F, Michaelis A, Markel F, Brosig S, Gebauer RA, Dähnert I, Paech C. Reference Values for Mobile Open Field Stress Testing in Healthy Children Aged 4 to 8 Years. Thorac Cardiovasc Surg 2022. [DOI: 10.1055/s-0042-1742960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- P. Kalden
- Universitätsklinik für Kinderkardiologie, Heart Center Leipzig, Leipzig, Deutschland
| | - I. Schoeffl
- Department of Pediatric Cardiology, University Hospital Erlangen, Erlangen, Deutschland
| | | | - F. Löffelbein
- Universitätsklinik für Kinderkardiologie, Leipzig, Deutschland
| | - A. Michaelis
- Kinderkardiologie, Herzzentrum Leipzig, Leipzig, Deutschland
| | - F. Markel
- Universitätsklinik für Kinderkardiologie, Leipzig, Deutschland
| | - S. Brosig
- Kinderkardiologie, Herzzentrum Leipzig, Leipzig, Deutschland
| | - R. A. Gebauer
- Kinderkardiologie, Herzzentrum Leipzig, Leipzig, Deutschland
| | - I. Dähnert
- Kinderkardiologie, Herzzentrum Leipzig, Leipzig, Deutschland
| | - C. Paech
- Universitätsklinik für Kinderkardiologie, Leipzig, Deutschland
| |
Collapse
|